Pavlos Msaouel, MD
Combining nivolumab (Opdivo) with sitravatinib induced a confirmed objective response rate (ORR) of 39% and a 92% clinical benefit rate in patients with advanced clear cell renal cell carcinoma (ccRCC).1
The efficacy data showed confirmed objective responses in 39% (n = 15) of the 38 efficacy-evaluable patients. One patient had an unconfirmed complete response. Stable disease was the best response for 20 patients. The results compared favorably with historical results for other agents, Msaouel noted: 3% to 5% for everolimus and 17% to 21% for cabozantinib (Cabometyx).
<<< View more from the 2020 Genitourinary Cancers Symposium
- Msaouel P, Thall PF, Yuan Y, et al. A phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy. J Clin Oncol. 2020;38(suppl 6; abstr 612). bit.ly/2URLoa6.
- Pant S, Spira AI, Cho BC, et al. Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT). J Clin Oncol. 2018;36(suppl 15; abstr 4568). doi: 10.1200/JCO.2018.36.15_suppl.4568.
- Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813. doi: 10.1056/NEJMoa1510665.
... to read the full story